Publications by authors named "Francesco Forconi"

Claim this Profile
I
Identification, assembly and characterization of tumor immunoglobulin transcripts from RNA sequencing data using IgSeqR.
Dean Bryant, Benjamin Sale, Giorgia Chiodin, Dylan Tatterton, Benjamin Stevens, Francesco Forconi

Nat Protoc· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The origin, diagnosis, and prognosis of oligomannose-type diffuse large B-cell lymphoma.
Dylan J Tatterton, Maddy L Newby, Joel D Allen, Benjamin Sale, Giorgia Chiodin, Francesco Forconi

Blood· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Measurable Residual Disease-Guided Therapy for Chronic Lymphocytic Leukemia.
Talha Munir, Sean Girvan, David A Cairns, Adrian Bloor, David Allsup, Francesco Forconi

N Engl J Med· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CD40L and IL-4 suppress NK cell-mediated antibody-dependent cellular cytotoxicity through the HLA-E:NKG2A axis.
Lara V Graham, Ludmila Horehajova, Marco V Haselager, Jack G Fisher, Jamie Lee Roos, Francesco Forconi

Immunother Adv· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FoxO1/Rictor axis induces a nongenetic adaptation to ibrutinib via Akt activation in chronic lymphocytic leukemia.
Laura Ondrisova, Vaclav Seda, Krystof Hlavac, Petra Pavelkova, Eva Hoferkova, Francesco Forconi

J Clin Invest· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
KIR2DS2+ NK cells in cancer patients demonstrate high activation in response to tumour-targeting antibodies.
Lara V Graham, Jack G Fisher, Amber D P Doyle, Ben Sale, Luis Del Rio, Francesco Forconi

Front Oncol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hairy cell leukemia variant and WHO classification correspondence Re: 5 edition WHO classification haematolymphoid tumors: lymphoid neoplasms.
Michael Grever, Leslie Andritsos, Mirela Anghelina, Evgeny Arons, Versha Banerji, Francesco Forconi

Leukemia· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Time for a new prognostic score in CLL?
Francesco Forconi

Blood· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Activity of venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia: analysis of the VENICE-1 multicentre, open-label, single-arm, phase 3b trial.
Arnon P Kater, Önder Arslan, Fatih Demirkan, Yair Herishanu, Burhan Ferhanoglu, Francesco Forconi

Lancet Oncol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The essential microenvironmental role of oligomannoses specifically inserted into the antigen-binding sites of lymphoma cells.
Freda K Stevenson, Francesco Forconi

Blood· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease.
Talha Munir, David A Cairns, Adrian Bloor, David Allsup, Kate Cwynarski, Francesco Forconi

N Engl J Med· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
X
XPO1 inhibition sensitises CLL cells to NK cell mediated cytotoxicity and overcomes HLA-E expression.
Jack G Fisher, Amber D P Doyle, Lara V Graham, Shreyanshi Sonar, Ben Sale, Francesco Forconi

Leukemia· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term benefit of IGHV mutated patients in a real-life multicenter cohort of FCR-treated chronic lymphocytic leukemia.
Riccardo Moia, Riccardo Dondolin, Maria Stefania De Propris, Donatella Talotta, Samir Mouhssine, Francesco Forconi

Hematol Oncol· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Network analysis reveals a major role for 14q32 cluster miRNAs in determining transcriptional differences between IGHV-mutated and unmutated CLL.
Dean Bryant, Lindsay Smith, Karly Rai Rogers-Broadway, Laura Karydis, Jeongmin Woo, Francesco Forconi

Leukemia· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib.
Silvia Bonfiglio, Lesley-Ann Sutton, Viktor Ljungström, Antonella Capasso, Tatjana Pandzic, Francesco Forconi

Blood Adv· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial.
Peter Hillmen, Alexandra Pitchford, Adrian Bloor, Angus Broom, Moya Young, Francesco Forconi

Lancet Oncol· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BCL2 Inhibition in Refractory Hairy-Cell Leukemia.
Francesco Forconi, Margaret Ashton-Key, Nicola Meakin

N Engl J Med· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of a distributed international patient data registry for hairy cell leukemia.
Leslie A Andritsos, Mirela Anghelina, Jasmine Neal, James S Blachly, Puneet Mathur, Francesco Forconi

Leuk Lymphoma· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia.
Farhad Ravandi, Robert J Kreitman, Enrico Tiacci, Leslie Andritsos, Versha Banerji, Francesco Forconi

Blood Cancer J· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High surface IgM levels associate with shorter response to ibrutinib and BTK bypass in patients with CLL.
Giorgia Chiodin, Samantha Drennan, Enrica A Martino, Laura Ondrisova, Isla Henderson, Francesco Forconi

Blood Adv· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of metabolic alterations of chronic lymphocytic leukemia in the lymph node microenvironment.
Zhenghao Chen, Helga Simon-Molas, Gaspard Cretenet, Beatriz Valle-Argos, Lindsay D Smith, Francesco Forconi

Blood· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BTK-independent regulation of calcium signalling downstream of the B-cell receptor in malignant B-cells.
Rachael Arthur, Alexander Wathen, Elizabeth A Lemm, Freda K Stevenson, Francesco Forconi

Cell Signal· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
KIR2DS2 Expression Identifies NK Cells With Enhanced Anticancer Activity.
Matthew D Blunt, Andres Vallejo Pulido, Jack G Fisher, Lara V Graham, Amber D P Doyle, Francesco Forconi

J Immunol· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Mutations Identified Using NGS Comprise the Overwhelming Majority of Disruptions in CLL: Results From a Multicentre Study.
Mark A Catherwood, Dorte Wren, Laura Chiecchio, Doriane Cavalieri, David Donaldson, Francesco Forconi

Front Oncol· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
B-cell receptor dependent phagocytosis and presentation of particulate antigen by chronic lymphocytic leukemia cells.
Annabel R Minton, Lindsay D Smith, Dean J Bryant, Jonathan C Strefford, Francesco Forconi

Explor Target Antitumor Ther· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis